SE8302130L - Farmakologiskt aktiva bifosfonater, forfarande for deras framstellning och farmaceutiska kompositioner innehallande desamma - Google Patents

Farmakologiskt aktiva bifosfonater, forfarande for deras framstellning och farmaceutiska kompositioner innehallande desamma

Info

Publication number
SE8302130L
SE8302130L SE8302130A SE8302130A SE8302130L SE 8302130 L SE8302130 L SE 8302130L SE 8302130 A SE8302130 A SE 8302130A SE 8302130 A SE8302130 A SE 8302130A SE 8302130 L SE8302130 L SE 8302130L
Authority
SE
Sweden
Prior art keywords
biphosphonates
procedure
preparation
pharmaceutical compositions
compositions containing
Prior art date
Application number
SE8302130A
Other languages
Unknown language ( )
English (en)
Other versions
SE463239B (sv
SE8302130D0 (sv
Inventor
S Rosini
G Staibano
Original Assignee
Gentili Ist Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11171970&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE8302130(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gentili Ist Spa filed Critical Gentili Ist Spa
Publication of SE8302130D0 publication Critical patent/SE8302130D0/sv
Publication of SE8302130L publication Critical patent/SE8302130L/sv
Publication of SE463239B publication Critical patent/SE463239B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3856—Polyphosphonic acids containing halogen or nitro(so) substituents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE8302130A 1982-04-15 1983-04-15 Farmaceutiskt aktiva bifosfonater samt farmaceutiska kompositioner innehaallande desamma SE463239B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT8220781A IT1201087B (it) 1982-04-15 1982-04-15 Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche

Publications (3)

Publication Number Publication Date
SE8302130D0 SE8302130D0 (sv) 1983-04-15
SE8302130L true SE8302130L (sv) 1983-10-16
SE463239B SE463239B (sv) 1990-10-29

Family

ID=11171970

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8302130A SE463239B (sv) 1982-04-15 1983-04-15 Farmaceutiskt aktiva bifosfonater samt farmaceutiska kompositioner innehaallande desamma

Country Status (12)

Country Link
US (1) US4621077A (sv)
JP (1) JPS58189193A (sv)
BE (1) BE896453A (sv)
CH (1) CH661437A5 (sv)
FR (1) FR2525223B1 (sv)
GB (1) GB2118042B (sv)
HK (1) HK79390A (sv)
IT (1) IT1201087B (sv)
LU (2) LU88714I2 (sv)
MX (1) MX9203428A (sv)
NL (5) NL192562C (sv)
SE (1) SE463239B (sv)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8419489D0 (en) * 1984-07-31 1984-09-05 Leo Pharm Prod Ltd Chemical compounds
IL77243A (en) * 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
DE3512536A1 (de) * 1985-04-06 1986-10-16 Boehringer Mannheim Gmbh, 6800 Mannheim Neue diphosphonsaeure-derivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3540150A1 (de) * 1985-11-13 1987-05-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
IL86951A (en) * 1987-07-06 1996-07-23 Procter & Gamble Pharma Methylene phosphonoalkylphosphinates and pharmaceutical preparations containing them
US4963681A (en) * 1987-07-06 1990-10-16 Norwich Eaton Pharmaceuticals, Inc. Process for synthesis of aminomethylene phosphonoalkylphosphinates
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5227506A (en) * 1989-09-06 1993-07-13 Merck & Co., Inc. Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors
FI83657C (sv) * 1989-09-08 1991-08-12 Huhtamaeki Oy Förfarande för framställning av metylenbisfosfonsyror
US5356887A (en) * 1990-01-31 1994-10-18 Merck & Co., Inc. Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
GB2248061A (en) * 1990-09-18 1992-03-25 Merck & Co Inc Amino-hydroxy-alkylidene bis phosphonic acids
US5183815A (en) * 1991-01-22 1993-02-02 Merck & Co., Inc. Bone acting agents
IT1247034B (it) * 1991-06-26 1994-12-12 Gentili Ist Spa Acidi dimetilamino-idrossi alchil difosfonici e loro sali, loro procedimento produttivo e composizioni farmaceutiche che li comprendono
US6096342A (en) * 1997-03-12 2000-08-01 The Procter & Gamble Company Dosage forms of risedronate
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
TW237386B (sv) * 1992-04-15 1995-01-01 Ciba Geigy
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
US6406714B1 (en) 1992-12-02 2002-06-18 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids
US6399592B1 (en) 1992-12-23 2002-06-04 Merck & Co., Inc. Bishphosphonate/estrogen synergistic therapy for treating and preventing bone loss
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5591730A (en) * 1993-10-12 1997-01-07 The Regents Of The University Of California Inhibition of urinary calculi growth
US5854227A (en) * 1994-03-04 1998-12-29 Hartmann; John F. Therapeutic derivatives of diphosphonates
US20010007863A1 (en) * 1998-06-18 2001-07-12 Merck & Co., Inc. Wet granulation formulation for bisphosphonic acids
US5449819A (en) * 1994-06-06 1995-09-12 Merck & Co., Inc. Process for removing waste pox, alendronate and its by products
US6008206A (en) * 1994-09-21 1999-12-28 Merck & Co., Inc. Sodium alendronate preparation for local administration
JP3411690B2 (ja) * 1994-09-21 2003-06-03 帝人株式会社 局所投与用アレンドロン酸ナトリウム製剤
US20010051616A1 (en) * 1995-02-17 2001-12-13 David B. Karpf Method of lessening the risk of vertebral fractures
NZ303022A (en) * 1995-02-17 2000-07-28 Merck & Co Inc Treatment of osteoporotic diseases with alendronate
AU713824B2 (en) * 1995-05-12 1999-12-09 Merck Sharp & Dohme Corp. Prevention of tooth loss by the administration of alendronate or its salts
AU5973496A (en) 1995-06-06 1996-12-24 Merck & Co., Inc. Bisphosphonate cement composition to prevent aseptic loosening of orthopedic implant devices
WO1996039410A1 (en) * 1995-06-06 1996-12-12 Merck & Co., Inc. Disodium alendronate formulations
JP3344726B2 (ja) * 1995-06-06 2002-11-18 メルク エンド カンパニー インコーポレーテッド 無水アレンドロネート一ナトリウム塩製剤
EP1820497A3 (en) * 1996-05-17 2009-07-22 Merck & Co., Inc. Effervescent bisphosphonate formulation
CA2254060C (en) * 1996-05-17 2007-05-01 Merck & Co., Inc. Effervescent bisphosphonate formulation
EP1378234A1 (en) * 1996-05-17 2004-01-07 MERCK & CO. INC. Effervescent bisphosphonate formulation
BR9712197A (pt) * 1996-10-04 1999-08-31 Merck & Co Inc Formulação farmacêutica líquida aquosa e processos de preparação da mesma, e, de inibição de reabsorção de osso.
US6376477B2 (en) 1996-11-25 2002-04-23 Merck & Co., Inc. Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US6410782B1 (en) * 1997-07-09 2002-06-25 Geange Ltd. Diphosphonic acid salts for the treatment of osteoporosis
US5994329A (en) * 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US6416964B2 (en) 1998-01-29 2002-07-09 Merck & Co., Inc. Methods of identifying modulators of kinases responsive to stress
US6750340B2 (en) 1998-04-02 2004-06-15 Mbc Research, Inc. Bisphosphonate conjugates and methods of making and using the same
US6214812B1 (en) * 1998-04-02 2001-04-10 Mbc Research, Inc. Bisphosphonate conjugates and methods of making and using the same
US8586781B2 (en) * 1998-04-02 2013-11-19 Mbc Pharma, Inc. Bone targeted therapeutics and methods of making and using the same
US6896871B2 (en) 1998-04-02 2005-05-24 Mbc Research, Inc. Biphosphonate conjugates and methods of making and using the same
US7598246B2 (en) * 1998-04-02 2009-10-06 Mbc Pharma, Inc. Bisphosphonate conjugates and methods of making and using the same
US20030078211A1 (en) * 1998-06-24 2003-04-24 Merck & Co., Inc. Compositions and methods for inhibiting bone resorption
WO1999067809A1 (en) 1998-06-24 1999-12-29 Merck & Co., Inc. Compositions and methods for inhibiting bone resorption
US6008207A (en) * 1998-08-13 1999-12-28 Merck & Co., Inc. Anhydrous alendronate monosodium salt formulations
DE69932620T2 (de) * 1998-08-27 2006-12-14 Teva Pharmaceutical Industries Ltd. Hydratformen des natriumsalzes von alendronat, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die diese enthalten
US6331533B1 (en) 1998-11-16 2001-12-18 Merck & Co., Inc. Method for inhibiting dental resorptive lesions
DE60012165T2 (de) * 1999-02-17 2005-08-25 Teva Pharmaceutical Industries Ltd. Verfahren zur herstellung von alendron-säure
US7205404B1 (en) * 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
AR024462A1 (es) 1999-07-01 2002-10-02 Merck & Co Inc Tabletas farmaceuticas
SE9903345D0 (sv) * 1999-09-17 1999-09-17 Astra Pharma Prod Novel process
KR100317935B1 (ko) * 1999-10-20 2001-12-22 유승필 대사성 골질환 치료용 약제조성물 및 이의 제조방법
AR021347A1 (es) * 1999-10-20 2002-07-17 Cipla Ltd Una composicion farmaceutica que contiene acido(s) bisfosfoncio o sal(es) del mismo y un proceso de preparacion de la misma
US6677320B2 (en) 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
PE20011061A1 (es) 2000-02-01 2001-11-20 Procter & Gamble Cristalizacion selectiva del acido 3-piridil-1-hidroxi-etiliden-1,1-bisfosfonico sodio como el hemipentahidrato o el monohidrato
PE20011065A1 (es) 2000-02-01 2001-11-21 Procter & Gamble Proceso para fabricar bisfosfonatos geminales
US6468559B1 (en) 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
US6476006B2 (en) 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
US6638920B2 (en) * 2000-07-21 2003-10-28 Merck & Co., Inc. Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
US20040038946A1 (en) * 2001-04-27 2004-02-26 Wilson Lon J. Fullerene-based drugs targeted to bone
ES2268086T3 (es) * 2001-05-02 2007-03-16 Novartis Ag Metodo de administracion de bisfosfonatos por inhalacion en el tratamiento o prevencion de la resorcion osea y la osteoporosis.
US20030216358A1 (en) * 2001-07-05 2003-11-20 Muchmore Douglas Boyer Method for enhancing bone mineral density gain
US20050070504A1 (en) * 2001-12-21 2005-03-31 The Procter & Gamble Co. Risedronate compositions and their methods of use
MXPA04006027A (es) * 2001-12-21 2004-09-27 Procter & Gamble Metodo para el tratamiento de trastornos de los huesos.
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
US7488496B2 (en) * 2002-03-06 2009-02-10 Christer Rosen Effervescent compositions comprising bisphosphonates and methods related thereto
US20050176685A1 (en) * 2002-04-05 2005-08-11 Daifotis Anastasia G. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
ITMI20020908A1 (it) * 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione di sodio alendronato
JP2005522526A (ja) 2002-05-10 2005-07-28 エフ．ホフマン−ラ　ロシュ　アーゲー 骨粗鬆症の治療および予防用のビスホスホン酸
CN1665825A (zh) * 2002-05-17 2005-09-07 特瓦制药工业有限公司 用一定的稀释剂制备双膦酸
US20040137058A1 (en) * 2002-07-09 2004-07-15 Katdare Ashok V. Effervescent bisphosphonate formulation
US20040138180A1 (en) * 2002-10-03 2004-07-15 Barr Laboratories, Inc. Bisphosphonate composition and process for the preparation thereof
EP1790347B1 (en) * 2002-12-20 2014-12-24 F. Hoffmann-La Roche AG High dose ibandronate formulation
US20040206932A1 (en) * 2002-12-30 2004-10-21 Abuelyaman Ahmed S. Compositions including polymerizable bisphosphonic acids and methods
CN1325506C (zh) * 2003-05-15 2007-07-11 中国科学院上海药物研究所 骨重吸收抑制剂阿伦膦酸及生理可接受的盐和它的制备
EP2279722B1 (en) * 2003-08-12 2013-05-01 3M Innovative Properties Company Self-etching dental compositions and its use
EP1667691A1 (en) * 2003-09-19 2006-06-14 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate
US20050181043A1 (en) * 2004-02-12 2005-08-18 Indranil Nandi Alendronate salt tablet compositions
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
JP4605221B2 (ja) 2004-05-24 2011-01-05 味の素株式会社 キレート剤を含有するビスホスホネートの腸溶性で固形の経口剤形
KR100564628B1 (ko) * 2004-06-16 2006-03-28 삼성전자주식회사 스플릿 게이트형 플래쉬 메모리 소자 및 그 제조방법
AU2005269869B2 (en) 2004-07-08 2011-12-01 3M Innovative Properties Company Dental methods, compositions, and kits including acid-sensitive dyes
JP5037342B2 (ja) 2004-08-11 2012-09-26 スリーエム イノベイティブ プロパティズ カンパニー 複数の酸性化合物を含む粘着性組成物
WO2006039721A2 (en) * 2004-10-08 2006-04-13 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
WO2008128056A1 (en) * 2004-10-08 2008-10-23 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including fpps, ggpps, and dpps
CN1304401C (zh) * 2004-12-28 2007-03-14 浙江工业大学 一种阿伦膦酸的制备方法
US8158153B2 (en) * 2005-03-17 2012-04-17 Alkermes Pharma Ireland Limited Nanoparticulate bisphosphonate compositions
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
US20070087052A1 (en) * 2005-10-19 2007-04-19 Katdare Ashok V Effervescent bisphosphonate formulation
DE112007000280A5 (de) 2006-02-03 2008-10-30 HÄRING, Thomas Phosphonsäure-haltige Blends und Phosphonsäure-haltige Polymere
AU2007226964B2 (en) * 2006-03-17 2012-03-22 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods
CA2658834A1 (en) * 2006-11-21 2008-05-29 Teikoku Pharma Usa, Inc. Bisphosphonate inhalant formulations and methods for using the same
WO2008076739A2 (en) 2006-12-13 2008-06-26 3M Innovative Properties Company Methods of using a dental composition having an acidic component and a photobleachable dye
US20080182823A1 (en) * 2007-01-26 2008-07-31 Hidesmasa Katsumi Polymer-linked-biophosphonate inhalant formulations and methods for using the same
JP2011517313A (ja) 2007-12-11 2011-06-02 ビアメト ファーマシューティカルズ，インク． 金属結合部分を標的化部分と組み合わせて使用する金属酵素阻害剤
WO2009100107A2 (en) * 2008-02-05 2009-08-13 Actavis Group Ptc Ehf Alendronate formulations, method of making and method of use thereof
US7964584B2 (en) * 2008-08-01 2011-06-21 Dong Wha Pharmaceutical Co., Ltd. Method of treating or preventing osteoporosis comprising administering to a patient in need thereof an effective amount of pharmaceutical composition comprising benzamidine derivatives or their salts, and alendronic acid or its salt
US20100034752A1 (en) * 2008-08-11 2010-02-11 Toru Hibi Inhalant formulations comprising a bisphosphonate and a pyrazolone derivative and methods for using the same
FR2954320B1 (fr) 2009-12-17 2012-06-15 Cll Pharma Composition pharmaceutique orale suprabiodisponible contenant un acide biphosphonique ou un de ses sels
RU2640582C2 (ru) 2011-08-01 2018-01-10 Мбс Фарма, Инк. Производные витамина в6 нуклеотидов, ациклических нуклеотидов и ациклических нуклеозидных фосфонатов
GB201200868D0 (en) 2012-01-19 2012-02-29 Depuy Int Ltd Bone filler composition
EP3105238A4 (en) 2014-02-13 2017-11-08 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
PL407922A1 (pl) 2014-04-16 2015-10-26 Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością Nowe bisfosfoniany i ich zastosowanie
EP3164136A4 (en) 2014-07-02 2018-04-04 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
US11970482B2 (en) 2018-01-09 2024-04-30 Ligand Pharmaceuticals Inc. Acetal compounds and therapeutic uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143123A (en) * 1966-05-18 1969-02-19 Albright & Wilson Mfg Ltd Phosphate compositions
GB1235029A (en) * 1966-12-29 1971-06-09 Procter & Gamble Stannous polyphosphonates and their use in oral compositions for caries prophylaxis
PH9776A (en) * 1967-12-11 1976-03-17 M Francis Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue and method of use
US3683080A (en) * 1970-08-28 1972-08-08 Procter & Gamble Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue
PH9853A (en) * 1972-06-08 1976-04-13 M Francis Compositions for inhibiting mobilization of calcium phosphate in animal tissue and method of use thereof
IE37842B1 (en) * 1972-06-30 1977-10-26 Procter & Gamble Oral compositions for plaque caries and calculus retardation with reduced staining tendencies
GB1453667A (en) * 1973-05-23 1976-10-27 Procter & Gamble Radionuclide-labelled phosphonic acids for the treatment of calcific tumours
DE2405254C2 (de) * 1974-02-04 1982-05-27 Henkel KGaA, 4000 Düsseldorf Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper
US3987157A (en) * 1974-08-29 1976-10-19 Union Carbide Corporation Technetium 99-m labeled radio-diagnostic agents employing stannous tartrate and method of preparation
DE2534391C2 (de) * 1975-08-01 1983-01-13 Henkel KGaA, 4000 Düsseldorf 1-Hydroxy-3-aminoalkan-1,1-diphosphonsäuren
JPS5283957A (en) * 1975-12-01 1977-07-13 Henkel & Cie Gmbh Medicine for treating metabolic obstruction of calcium
US4137309A (en) * 1976-10-14 1979-01-30 The Procter & Gamble Company Therapeutic treatment
US4275059A (en) * 1977-03-28 1981-06-23 The Procter & Gamble Company Salicylate anti-inflammatory composition
US4216211A (en) * 1977-10-31 1980-08-05 The Procter & Gamble Company Therapeutic composition
US4230700A (en) * 1977-12-07 1980-10-28 The Procter & Gamble Company Methods for inhibiting mobilization of calcium phosphate in animal tissue
US4330537A (en) * 1977-12-07 1982-05-18 The Procter & Gamble Company Compositions for inhibiting mobilization of calcium phosphate in animal tissue
US4216212A (en) * 1978-06-08 1980-08-05 The Procter & Gamble Company Pyrazolidine anti-inflammatory composition and methods of use
IT1097292B (it) * 1978-06-27 1985-08-31 Gentili Ist Spa Composizione farmaceutica per la terapia dell'ittero ostruttivo non neoplastico
US4282214A (en) * 1978-07-31 1981-08-04 The Procter & Gamble Company Phenylacetate anti-inflammatory composition
US4264582A (en) * 1978-07-31 1981-04-28 The Procter & Gamble Company Isobutylphenylacetate anti-inflammatory composition
US4254114A (en) * 1979-01-02 1981-03-03 The Proctor & Gamble Company Control of pyrophosphate microorganisms with organophosphonates
GB2043072B (en) * 1979-02-13 1983-11-23 Symphar Sa Diphosphonate compounds
GB2076889B (en) * 1980-03-12 1983-10-26 Cadbury Schweppes Transport Feeding fuel and water emulsion i c engines
DE3016289A1 (de) * 1980-04-28 1981-10-29 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren
GB2079285B (en) * 1980-07-09 1984-05-23 Symphar Sa Dipthosphonate derivatives and pahrmaceutical compositions containing them
GB2082585A (en) * 1980-08-27 1982-03-10 Vysoka Skola Chem Tech 6-amino-1-hydroxyhexylidene diphosphonic acid, salts thereof and a method of producing the acid and salts.
JPS5759900A (en) * 1980-09-29 1982-04-10 Vysoka Skola Chem Tech 6-amino-1-hydroxyhexylidene diphosphonic acid
BE890453A (fr) * 1980-10-07 1982-03-22 Procter & Gamble Procede d'inhibition des metastases de cellules tumorales
US4330530A (en) * 1980-12-22 1982-05-18 The Procter & Gamble Company Anti-arthritic compositions and method using gold salts and organophosphonates
IT1194748B (it) * 1981-02-12 1988-09-28 Gentili Ist Spa Composizioni farmaceutiche per il trattamento di osteopatie

Also Published As

Publication number Publication date
JPH0213645B2 (sv) 1990-04-04
IT8220781A0 (it) 1982-04-15
NL970038I1 (nl) 1998-01-05
LU88714I2 (fr) 1996-08-23
NL8301324A (nl) 1983-11-01
GB2118042A (en) 1983-10-26
IT1201087B (it) 1989-01-27
GB2118042B (en) 1986-01-15
US4621077A (en) 1986-11-04
NL192562C (nl) 1997-10-03
LU84746A1 (fr) 1983-11-17
MX9203428A (es) 1992-07-01
CH661437A5 (it) 1987-07-31
NL970038I2 (nl) 2000-11-01
BE896453A (fr) 1983-08-01
NL980010I1 (nl) 1998-05-06
NL980004I1 (nl) 1998-04-01
HK79390A (en) 1990-10-12
JPS58189193A (ja) 1983-11-04
NL192562B (nl) 1997-06-02
FR2525223B1 (fr) 1986-04-25
NL980005I1 (nl) 1998-04-01
SE463239B (sv) 1990-10-29
SE8302130D0 (sv) 1983-04-15
GB8308791D0 (en) 1983-05-11
FR2525223A1 (fr) 1983-10-21

Similar Documents

Publication Publication Date Title
SE8302130L (sv) Farmakologiskt aktiva bifosfonater, forfarande for deras framstellning och farmaceutiska kompositioner innehallande desamma
DE3567870D1 (en) Xanthine derivatives, processes for their preparation and pharmaceutical compositions containing them
ES2036190T3 (es) Nuevos derivados de acidos difosfonicos, procedimiento para su preparacion y medicamentos que contienen estos compuestos.
FI852980L (fi) Foerfarande foer framstaellning av nya difosfonsyraderivat.
ES504701A0 (es) Procedimiento para la preparacion de bis-(3,5-dicarbamoil-2,4,6-triyodo-anilidas)de acidos dicarboxilicos,hidroxialcohi-ladas en n
DE3270583D1 (en) Inhibitors of mammalian collagenase
SE8604950D0 (sv) Dementia-improving and therapeutic agents
DE3574256D1 (en) New cephem compounds, process for preparation thereof and pharmaceutical compositions containing them
FI834702A0 (fi) Nya nitroalifatiska foereningar, deras framstaellningsfoerfarande och anvaendning
DE3170937D1 (en) 2-(1,4-benzodioxan-2-ylalkyl) imidazoles, their preparation and pharmaceutical compositions containing them
KR890001965A (ko) 스퍼구알린 관련 유도체
IL69036A (en) Alpha-alkyl undecapentaenoic acids,pharmaceutical compositions containing the same and processes for the preparation thereof
AU565492B2 (en) 4-phenyl-4-oxo-buten-2-oic acids
ES2170758T3 (es) Antibioticos novedosos de cefalosporina y procedimientos para la preparacion de los mismos.
SE8205868D0 (sv) A titre de medicaments, certains derives de lŸacide 4-phenyl 4-oxo 2-butenoique et compositions les renfermant
ATE54142T1 (de) Hexensaeuren.
SE8302045L (sv) Furanderivat
ZA903111B (en) 2-hydroxy-3-phenoxypropylamino compounds and pharmaceutical compositions containing them
IL87796A0 (en) Substituted 3-aminosydnonimines,their preparation and pharmaceutical compositions containing them
ES555242A0 (es) Un procedimiento para la preparacion de nuevas 3-alcoxi-2-(n-pirrolidino)-n-piridil-n-furilmetilpropilaminas
IL71068A (en) N-(3-trifluoromethylphenyl)-n'-propargyl-piperazine,its preparation and pharmaceutical compositions containing it
JPS6450867A (en) Salts of thiamorpholinonecarboxylic acid and 2,4-diaminopyrimidine derivative and use for cosmetic and pharmaceutical composition
DE3373302D1 (en) Derivatives of aminopyridinecarboxylic acids, methods for their preparation and pharmaceutical compositions containing them
ES543798A0 (es) Procedimiento de preparacion de nuevos derivados 4-hidroxi- -a-etil-benzoles
SE8701887L (sv) Nya 4-fenyl-4-oxo-2-butensyraderivat, deras framstellningsforfarande, derasanvendning som lekemedel och kompositioner innehallande dem

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 8302130-3

Format of ref document f/p: F

SPCF Application for supplementary protection certificate filed

Free format text: 9590019, 950512

SPCG Supplementary protection certificate granted

Free format text: 9590019, 950512, EXPIRES: 20080415

NUG Patent has lapsed